Clinical Trial Detail

NCT ID NCT03515629
Title REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Regeneron Pharmaceuticals
Indications

non-small cell lung carcinoma

Therapies

Ipilimumab + REGN2810

Pembrolizumab

Age Groups: senior adult

Additional content available in CKB BOOST